The company achieved key milestones including successful DMC interim analysis review with no safety concerns, positive Phase 1 IV data showing rapid efficacy, secured $20.2M funding, and remains on track for mid-2026 topline data. Strong cash position ($46M) supports operations into H2 2027. However, net loss increased significantly YoY ($19.4M vs $10.3M), reflecting higher R&D spending on ongoing trials.
Also mentions CNTB
Articles that tag CNTB but are mainly about other companies.
None recently.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
